Status In progress
Process STA
ID number 1020

Provisional Schedule

Expected publication 24 January 2018

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Roche Products
Others Department of Health
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Pathologists

Commentators

Comparator companies Accord Healthcare (bendamustine, doxorubicin, etoposide, mitoxantrone) -(Confidentiality agreement not signed, not participating)
  Allergan (bendamustine, etoposide, prednisolone) -(Confidentiality agreement not signed, not participating)
  Aspen (chlorambucil)
  Bausch & Lomb UK (prednisolone) -(Confidentiality agreement not signed, not participating)
  Baxter Healthcare (cyclophosphamide, mitoxantrone) - (Confidentiality agreement not signed, not participating)
  Bayer (prednisolone) - (Confidentiality agreement not signed, not participating)
  Bristol-Myers Squibb (etoposide) (Confidentiality agreement not signed, not participating)
  Celltrion (rituximab) (Confidentiality agreement not signed, not participating)
  Concordia International (prednisolone) (Confidentiality agreement not signed, not participating)
  Dr. Reddy’s Laboratories (bendamustine) (Confidentiality agreement not signed, not participating)
  Hospira UK (mitoxantrone, vincristine) (Confidentiality agreement not signed, not participating)
  Intrapharm Laboratories (prednisolone) (Confidentiality agreement not signed, not participating)
  Janssen-Cilag (doxorubicin)
  Logixx Pharma Solutions (prednisolone) (Confidentiality agreement not signed, not participating)
  Medac GmbH (bendamustine, doxorubicin, etoposide) (Confidentiality agreement not signed, not participating)
  Merck Sharpe & Dohme (interferon alfa)
  Mundipharma (rituximab) (Confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (bendamustine)
  Pfizer (doxorubicin) (Confidentiality agreement not signed, not participating)
  Roche Products (interferon alfa, rituximab)
  Sandoz (cyclophosphamide) (Confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (doxorubicin) (Confidentiality agreement not signed, not participating)
  Teva UK (doxorubicin) (Confidentiality agreement not signed, not participating)
  Wockhardt UK (prednisolone) (Confidentiality agreement not signed, not participating)
  Zentiva (bendamustine, prednisolone) (Confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
18 October 2017 Committee meeting: 2
14 September 2017 - 05 October 2017 Appraisal consultation
22 August 2017 Committee meeting: 1
15 March 2017 Invitation to participate
19 September 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance